SunLike Series LEDs from Seoul Semiconductor Deliver Natural Spectrum Human-Centric Lighting Sources for European Lighting Designers
Seoul Semiconductor, a global leader and innovator of LED products and technology, exhibited its new SunLike Series LEDs, the world's first LED to produce light that closely matches the spectrum of natural sunlight, at the recent Professional Lighting Design Conference (PLDC), held in Paris, France from Nov. 1 – 4. The new LED technology, first unveiled in Frankfurt, Germany in June of this year, is generating interest from many global lighting companies, who are developing new lighting products using SunLike Series LEDs.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171113005607/en/
Seoul Semiconductor co-host of the opening event of PLDC in Paris, France. Yo Cho, director of Seoul Semiconductor's Lighting Divison explaining revolutionary SunLike Technology. (Photo: Business Wire)
New products from leading lighting designers powered by Seoul Semiconductor’s SunLike LED technology were on display at PLDC 2017, which attracted more than 2000 attendees. A number of these companies signaled their intention to launch these new SunLike-powered lighting products in the market.
The director of Seoul Semiconductor's Lighting Divison, Mr. Yo Cho, was invited as a keynote speaker at the PLDC’s opening event, where he presented SunLike Series LED technology. “Because the SunLike Series LEDs are designed to deliver light that closely matches sunlight’s natural spectrum, they provide an optimized light source that maximizes the benefits of natural light,” said Mr. Cho. “Thus, the colors and texture of objects can be viewed more accurately, as they would be seen under natural sunlight.”
According to Dr. Kibum Nam, Head of Seoul’s R&D Center and Chief Technology Officer , “SunLike Series LEDs have the potential to drive a revolution in lighting –overcoming the limits of artificial light sources by implementing light closer to the natural spectrum of sunlight. Seoul will open a new era of natural spectrum lighting with the launch of more SunLike LED technology.”
SunLike Series natural spectrum LEDs may also play a key role in minimizing the negative effects of artificial lighting. While conventional LED technology produces light with a pronounced blue “spike” in its spectral output, SunLike LEDs implement a more uniform spectrum that more closely matches natural sunlight, lowering this blue light spike. Some recent research indicates that this blue light spike may produce negative effects when viewed for prolonged periods of time during night-time hours, potentially interfering with natural human biorhythms. By employing new light sources powered by SunLike Series LEDs, lighting designers will be able to deliver a healthier light experience.
Interest in the link between light sources and human health is higher than ever before, as evidenced by the winners of this year’s Nobel Prize in Physiology, Professor Jeffrey C. Hall, University of Maine; Professor Michael Morris Rosbach, Brandeis University; and Professor Michael Young, Rockefeller University. These researchers are credited with seminal discoveries about the cellular mechanisms for circadian biology.
The SunLike Series natural spectrum LEDs are available from Seoul Semiconductor. To learn more about the SunLike Series natural spectrum LEDs, please visit: http://www.seoulsemicon.com/en/technology/Sunlike/
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; Wicop – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – World’s Smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers over 90 % NTSC.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks
Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005607/en/
Contact information
Contacts:
Europe
Seoul Semiconductor Europe GmbH
Ariane
Heim
Tel: +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
David Cox
Tel: +1 (919)
410-9856
Email: David.cox@seoulsemicon.com
or
Asia
Seoul
Semiconductor Co., Ltd
Jake Jung
Tel: +82 070.4391.8270
Email:
pr@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release
Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom